3 results
Approved WMORecruiting
The PLANCTON trial will investigate the effect of early intravenous OM-3 FAs on new onset organ failure and mortality in patients with predicted SAP.
Approved WMOCompleted
To evaluate the proportion of patients indicating an overall preference via a Patient Preference Questionnaire (PPQ) for either the subcutaneous (SC) or the intravenous (IV) route of rituximab administration.
Approved WMOCompleted
To determine the efficacy and safety of adding transdermal nitroglycerin to first line chemotherapy for advanced NSCLC.